4th Annual Jefferson Urology Symposium: Focus on Urinary Incontinence

© The Canadian Journal of Urology TM : International Supplement, August 2021 15. Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care 2009;15(4 Suppl):S118-S122. 16. Gormley EA, Lightner DJ, Burgio KL et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(6 Suppl):2455-2463. 17. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults:AUA/ SUFU guideline amendment 2019. J Urol 2019;202(3):558-563. 18. Balk E, Adam GP, Kimmel H et al. Nonsurgical treatments for urinary incontinence in women: a systematic review update. 2018. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK534625/ 19. Leron E, WeintraubAY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol 2018;11(3):117-125. 20. Kayki-Mutlu G, Michel MC. A year in pharmacology: new drugs approved by the US food and drug administration in 2020. Naunyn Schmiedebergs Arch Pharmacol 2021;394(5):839-852. 21. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review andmeta- analysis. Eur Urol 2008;54(3):543-562. 22. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429. 23. Risacher SL, McDonald BC, Tallman EF et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 2016;73(6):721-732. 24. Benner JS, Nichol MB, Rovner ES et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105(9):1276-1282. 25. Huang CK, Lin CC, Lin AT. Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting. Sci Rep 2020;10(1):11355. 26. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014;33(1):17-30. 27. Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 2020;204(2):316-324. 28. Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: A clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep 2012;13(5):327-334. 29. Gajewski JB, Hassouna MM, Corcos J, Gray GJ, Tu LM, Dwyer N. The history of sacral neuromodulation in Canada. Can Urol Assoc J 2020;14(4):87-90. 30. Gaziev G, Topazio L, Iacovelli V et al. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol 2013;13:61 31. Medtronic, Inc.; premarket approval of the interstim sacral nerve stimulation (SNS) system--FDA. notice. FedRegist 1998;63(19):4457. 32. DeWachter S, Knowles CH, EltermanDS et al. New technologies and applications in sacral neuromodulation: an update. Adv Ther 2020;37(2):637-643. 33. Das AK, White MD, Longhurst PA. Sacral nerve stimulation for themanagement of voiding dysfunction. RevUrol 2000;2(1):43-60. 34. Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med 2013;36(5):402-419. 35. Dmochowski R, Chapple C, Nitti VW et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184(6):2416-2422. 36. NittiVW,DmochowskiR,HerschornSet al.OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189(6):2186-2193. 37. ChappleC, SievertKD,MacDiarmidSet al.OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo- controlled trial. Eur Urol 2013;64(2):249-256. 38. Cruz F. Targets for botulinum toxin in the lower urinary tract. Neurourol Urodyn 2014;33(1):31-38. 39. Orasanu B, Mahajan ST. The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol 2013; 29(1):2-11. 40. Reyblat P, Ginsberg DA. Augmentation enterocystoplasty in overactive bladder: is there still a role? Curr Urol Rep 2010;11(6): 432-439. 41. Price N, Dawood R, Jackson SR. Pelvic floor exercise for urinary incontinence: a systematic literature review. Maturitas 2010;67(4):309-315. 42. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2018;10(10):CD005654. 43. Brook G, Tessema AB. Obstetric fistula: the use of urethral plugs for the management of persistent urinary incontinence following successful repair. Int Urogynecol J 2013;24(3):479-484. 44. Farrell SA, Singh B, Aldakhil L. Continence pessaries in the management of urinary incontinence in women. J Obstet Gynaecol Can 2004;26(2):113-117. 45. Chapple C, Dmochowski R. Particulate versus non-particulate bulking agents in the treatment of stress urinary incontinence. Res Rep Urol 2019;11:299-310. 46. Gaddi A, Guaderrama N, Bassiouni N, Bebchuk J, Whitcomb EL. Repeat midurethral sling compared with urethral bulking for recurrent stress urinary incontinence. Obstet Gynecol 2014;123(6):1207-1212. 47. Leone Roberti Maggiore U, Bogani G, Meschia M et al. Urethral bulking agents versus other surgical procedures for the treatment of female stress urinary incontinence: a systematic review andmeta-analysis. Eur J Obstet Gynecol Reprod Biol 2015; 189:48-54. 48. FordAA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2017;7(7):CD006375. 49. Kenton K, StoddardAM, Zyczynski H et al. 5-year longitudinal follow up after retropubic and transobturator mid urethral slings. J Urol 2015;193(1):203-210. 50. Athanasopoulos A, Gyftopoulos K, McGuire EJ. Efficacy and preoperative prognostic factors of autologous fascia rectus sling for treatment of female stress urinary incontinence. Urology 2011;78(5):1034-1038. 51. Chaikin DC, Rosenthal J, Blaivas JG. Pubovaginal fascial sling for all types of stress urinary incontinence: long-term analysis. J Urol 1998;160(4):1312-1316. 52. Morgan TO Jr, Westney OL, McGuire EJ. Pubovaginal sling: 4-year outcome analysis and quality of life assessment. J Urol 2000;163(6):1845-1848. 53. Albo ME, Richter HE, Brubaker L et al. Burch colposuspension versus fascial sling to reduce urinary stress incontinence. NEngl J Med 2007;356(21):2143-2155. 54. Fusco F, Abdel-FattahM, Chapple CR et al. Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence. Eur Urol 2017;72(4):567-591. Denisenko ET AL. 32